Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy
- 1 January 1984
- Vol. 54 (4), 744-750
- https://doi.org/10.1002/1097-0142(1984)54:4<744::aid-cncr2820540426>3.0.co;2-p
Abstract
Seventy-two patients with advanced prostatic carcinoma without previous endocrine therapy were treated with an oral nonsteroidal antiandrogen, flutamide. Sixty-three patients (87.5%) had a favorable response, and 9 patients showed no response. Flutamide appears to be a safe antiandrogen, usually effective in the management of patients with advanced prostatic cancer who have had no prior endocrine therapy.This publication has 9 references indexed in Scilit:
- Experience with Flutamide in Previously Untreated Patients With Advanced Prostatic CancerJournal of Urology, 1979
- Effect of Flutamide on Cortisol Metabolism*Journal of Clinical Endocrinology & Metabolism, 1978
- The Effect of Flutamide on Testosterone Metabolism and the Plasma Levels of Androgens and GonadotropinsJournal of Clinical Endocrinology & Metabolism, 1977
- Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostatic cancerUrology, 1976
- The Treatment of Benign Prostatic Hypertrophy with Flutamide (SCH 13521): A Placebo-Controlled StudyJournal of Urology, 1975
- Advanced prostatic carcinoma Flutamide therapy after conventional endocrine treatmentUrology, 1975
- Prostatic Cancer and Sch-13521: II. Histological Alterations and the Pituitary Gonadal AxisJournal of Urology, 1975
- Sch 13521 In The Treatment Of Advanced Carcinoma Of The ProstateJournal of Urology, 1974
- A Biological Profile of a Nonsteroidal Antiandrogen, SCH 13521 (4'–Nitro–3'–Trifluoromethylisobutyranilide)1Endocrinology, 1972